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Background: The Patient Perception of Intensity of Urgency Scale (PPIUS) is a patient-reported outcome
instrument intended to measure the intensity of urgency associated with each urinary or incontinence episode. The
objectives of this study were to assess the content validity, test-retest reliability, and acclimation effect of the PPIUS
in overactive bladder (OAB) patients.
Methods: Patients undergoing treatment for OAB were recruited to participate in a non-interventional study by
completing a three-day micturition diary including the PPIUS for three consecutive weeks. Following completion of
the three-week study, participants from two select sites also completed a cognitive interview to assess their
comprehension of the PPIUS.
Results: Thirty-nine participants successfully completed the three-week test-retest study; twelve of these
participants completed the cognitive interview. Test-retest reliability was high based on intra-class correlation
coefficient of 0.95. Among stable patients, the difference between the mean ratings of any two weeks was non-
significant. Among the twelve interview participants, nine found it simple to choose a PPIUS rating for each of their
micturition episodes and most found the urgency rating definitions consistent with their urgency experiences.
Conclusions: The results demonstrated content validity based on qualitative interviews, and excellent test-retest
reliability among stable patients. In addition, no acclimation effect was observed among stable patients. These
findings support the use of the PPIUS as a reliable measure of urgency in both clinical trial and real life settings. The
validity of PPIUS could be further established with future studies investigating the relationship between discretely
graded urgency and incontinence continuum.
Keywords: Over active bladder, OAB, Urinary urgency, Urge incontinence, Patient perception of intensity of
urgency scale, PPIUSBackground
Overactive bladder syndrome (OAB), according to the
Standardization Subcommittee of the International Con-
tinence Society (ICS), is a symptom-defined condition
characterized by urinary urgency, usually with urinary
frequency and nocturia, and may or may not be accom-
panied by urge incontinence [1]. OAB has been shown
to cause significant symptomatic burden and disrupt* Correspondence: wen-hung.chen@unitedbiosource.com
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reproduction in any medium, provided the ordaily activities, sleep, and personal relationships [2]. It is
common in clinical practice to ask patients to use a
diary to record urinary episodes of their OAB symptoms.
However, few existing questionnaires ask about the in-
tensity of the urgency, one of the key symptoms of OAB,
which can have as much of an impact as the frequency
of urinary urgency [2].
The Patient Perception of Intensity and Urgency Scale
(PPIUS) has been recommended when assessing the de-
gree of urgency felt by patients at each micturition [3].
The PPIUS is a 5-point scale designed for measurement
of both urinary urgency and urge incontinence. It hastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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used in OAB clinical trials [4-6]. Cartwright, Srikrishna,
Cardazo, & Robinson [7] found that the PPIUS has good
reliability, excellent known groups validity and conver-
gent validity, and high responsiveness when used in a
clinical trial study with adult women with OAB. The
test-retest reliability of the PPIUS incorporated into a
seven-week diary completed before and after a one-week
interval has been reported in a group of asymptomatic
women [8]. However, content validity has yet to be sup-
ported with qualitative research in patients with OAB.
Furthermore, the possibility of an acclimation effect has not
been examined among patients with OAB. Acclimation
effects exist when data initially collected (i.e., the first
week) are significantly different from data collected after
patients become familiar with the diary, rendering the ini-
tial data unreliable.
The objective of this study was to assess the content
validity of the PPIUS, the test-retest reliability of the
mean PPIUS urgency ratings in men and women with
symptoms of OAB, and whether OAB patients demon-




Males and females over the age of 18 years old with clin-
ical records that described symptoms of OAB for at least
three months and on continuous treatment for OAB for
at least three months (based on clinician-report/pre-
scription) were eligible for this study. These symptoms
included frequency, urgency, nocturia, and/or urge in-
continence. The patients were not required to undergo
the urodynamic testing (UDS) for this study. Exclusion
criteria were as follows: pregnant or breastfeeding
women; significant stress incontinence or mixed stress/
urge incontinence where stress is the predominant factor
as determined by site study staff; self-catheterization;
diabetic neuropathy; urinary tract infection (confirmed
by dipstick test); non-drug treatment, including electro-
stimulation therapy; any clinically significant condition
or visual or cognitive impairment which in the opinion
of the investigator makes the subject unsuitable for the
study. Patients were recruited from five clinical sites in
the different states in the United States (US): Oklahoma,
California, Utah, Ohio, and Massachusetts. Recruitment
was on a continuous basis and lasted approximately two
months until recruitment goals were met. The study
protocol was approved by Ethical Review Committee,
Inc. (Independence, MO) (ERC ID #485-07-09). In
addition, all recruitment procedures met Health Insur-
ance Portability and Accountability Act of 1996 require-
ments and approval standards, and all applicable state
and federal laws and regulations. An estimated samplesize of 36 stable participants was required in order to
achieve 90% statistical power at a 2-sided 5% significance
test for an intra-class correlation coefficient (ICC) of
0.80 versus 0.50 [9].
Patients were first recruited to participate in a two-
visit non-interventional study to assess the test-retest re-
liability of the PPIUS. Following completion of the two-
visit study, successful completers of the test-retest study
from two geographically diverse and high-recruiting sites
were asked to participate in a third visit, consisting of a
one-on-one cognitive interview to evaluate their com-
prehension and understanding of the PPIUS, and pro-
vide evidence of content validity. Participants from the
two selected sites who agreed to participate in the cogni-
tive interview were scheduled 1–2 weeks after they com-
pleted the test-retest study.
At the first clinic visit, participants were trained by site
study staff on how to complete the PPIUS as a part of a
three-day diary at home over the following three con-
secutive weeks. Participants mailed back the Week 1 and
Week 2 diaries to the clinical site immediately upon
completion, and returned the Week 3 PPIUS diary to
the site at the second clinic visit (3 weeks + 5 days from
the first clinic visit). Following the completion of the
second visit, two select sites also recruited participants
who successfully completed the three-week study to par-
ticipate in a cognitive interview to assess their compre-
hension of the PPIUS. This cognitive interview was
designated as the third visit.
Study questionnaires
Patient perception of intensity of urgency questionnaire
(PPIUS)
The PPIUS is part of a daily micturition diary to be com-
pleted for three days in a given week. Participants were
instructed to record for each urinary episode throughout
the day: the time of urination, whether the episode was
an urination (defined as passed urine into the toilet) or
incontinence (defined as involuntary release of urine),
and the “degree of associated urgency according to the
definitions provided” (Figure 1). The PPIUS uses a 5-
point scale for measurement of both urinary urgency
and urge incontinence. Responses range from “No ur-
gency” to “Mild urgency,” “Moderate urgency,” “Severe
urgency,” and “Urge incontinence.” The definitions pro-
vided for the urgency ratings are listed in Table 1.
Patient- and clinician-completed overall treatment effect
The Overall Treatment Effect (OTE-Patient and OTE-
Clinician) assesses patients’ change in symptoms since
the previous study visit. The questions ask the patient/
clinician to indicate whether OAB symptoms have
improved, remained the same, or worsened since the last
study visit.[10-12] The OTE-Patient and OTE-Clinician
Figure 1 Urination episode entry field in the micturition diary.
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patients at the end of the three-week study in order to
assess test-retest reliability.
RAND 36-item short form health questionnaire
The validated RAND 36-item short form questionnaire is a
commonly used generic instrument designed to measure
health-related quality of life [13]. The questionnaire consists
of 36 items pertaining to the following eight health categor-
ies: physical functioning, social functioning, role limitations
due to physical health problems, role limitations due to
emotional problems, pain, mental health, vitality, and gen-
eral health perceptions. The RAND-36 was administered at




Descriptive statistics were used to summarize demo-
graphic information collected from the participant and
clinical information collected by the clinician at the first
visit, as well as the number of micturition per 24 hours,
number of incontinence episodes per 24 hours, and the
PPIUS mean scores. Categorical variables derived from
the OTE-Patient and the OTE-Clinician were also sum-
marized. A micturition was defined as an entry in the
diary with a checked “urinated” box. An incontinence
episode was defined as an entry in the diary with
checked “incontinence” box. If no “incontinence” box
was checked for a given day, the number of incontinence
episodes was set as zero for that day.Table 1 Definition and scale of Patient Perception of Intensity
Urinated: Passed urine
Incontinence: Involuntary re
Urge Incontinence: Involuntary re
Urgency:
0 No urgency I felt no need
1 Mild urgency I could postp
2 Moderate urgency I could postp
3 Severe urgency I could not p
4 Urge incontinence I leaked befo
Patient- and clinician-completed overall treatment effect.The daily PPIUS score was the mean of all
reported urgency ratings on that day (including day-
time and nighttime—a diary day starts when the
subject gets up with the intention of staying awake
and ends on the following day when the subject gets
up). The mean level of urgency for a given week
was the mean of the non-missing PPIUS daily scores
over the three-day micturition diary period of the
corresponding week.
Test-retest reliability
Data from participants whose OAB health state was
classified as stable between the first and second
clinic visits were used for assessment of reproducibil-
ity. Two definitions of stable patients were used and
two separate analyses of reproducibility were per-
formed. First, a stable patient was defined as those
who responded “about the same,” “almost the same,
hardly better at all,” or “almost the same, hardly
worse at all” on the OTE-Patient [10-12]. Second, a
stable patient was defined those who were classified
as “about the same,” “almost the same, hardly better
at all,” or “almost the same, hardly worse at all”
based on the OTE-Clinician.
The assessment of reproducibility was conducted by
comparing the stable patients’ PPIUS mean level of ur-
gency during Week 2 and Week 3. The test-retest reli-
ability was assessed through paired t-tests, Spearman
correlation, and ICC, and it was assumed that the ICC
should be greater than 0.80 which represented good to
excellent test-retest reliability [14].of Urgency Scale (PPIUS)
in the toilet.
lease of urine.
lease of urine accompanied or immediately preceded by urgency
to empty my bladder, but did so for other reasons.
one voiding as long as necessary, without fear of wetting myself.
one voiding for a short while, without fear of wetting myself.
ostpone voiding, but had to rush to the toilet in order not to wet myself.
re arriving to the toilet.
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Acclimation effect of the PPIUS was assessed by com-
paring the mean level of urgency at Weeks 1, 2, and 3 of
the stable patients defined based on the OTE-Patient.
Paired t-tests were used to assess whether the PPIUS
mean level of urgency was significantly different between
Week 1 and Week 2, between Week 2 and Week 3, and
between Week 1 and Week 3.
Qualitative analysis
Cognitive interviews were conducted to gather feedback
from the participants as an assessment of the content valid-
ity of the PPIUS. Participants were interviewed by a trained
interviewer from United BioSource Corporation (UBC)
using a standardized semi-structured interview guide with a
think-aloud approach. The interview guide provided instruc-
tions for conducting the interview and for questioning the
patients on their understanding of the PPIUS content and
how they selected the PPIUS ratings. The interview guide
included questions on the daily diary instructions, item con-
tent, and response scales. All interviews were audio recorded
and transcribed.
Content analysis and descriptive statistics were used to
analyze the responses collected during the cognitive
interviews. Qualitative data was analyzed using ATLAS.
ti software [15]. Using ATLAS.ti, qualitative data (patient
quotes from interviews) were systematically analyzed,
coded, and compared. “Open coding” was performed to
fracture the data (i.e., passages from transcripts and
notes) into smaller units and identifying concepts,
themes, or recurring regularities that appeared within
each interview. Axial coding was then used to connect
categories and subcategories of the data. Specifically,
each of the detailed codes or categories in open coding
was connected based on their emergent theoretical lin-
kages so that they represented specific instances of more
general, abstract phenomena or processes.
Results
Patient disposition
A total of 81 respondents were screened for eligibility,
and a total of 44 participants were eligible and consented
for the study. Of the 44 consented participants, 43 parti-
cipants completed the first clinic visit and 41 partici-
pants completed the second clinic visit. Forty-one
participants completed three-day diaries for Week 1 and
Week 2, however only 39 participants completed both
clinical visits and all three weeks of the three-day diaries.
These 39 participants were defined as the completers.
Reasons for discontinuation after consent included
screen failure due to positive urinary tract infection
(UTI) dipstick test (n = 1), change in medication (n = 1),
non-compliance with diary completion (n = 1), and loss
to follow up (n = 2).Twelve of the 39 successful completers of the test-
retest study also completed the cognitive interview (third
visit).Sociodemographic and clinical characteristics
Demographic and clinical characteristics reported by
patients are summarized in Table 2 for the 39 partici-
pants who completed the test-retest study and the 12
successful completers who also completed the cognitive
interviews. The mean (standard deviation [SD]) age of
the 39 participants was 59.1 (15.23) years and most par-
ticipants were Caucasian (n = 27, 69.2%), female (n = 32,
82.1%), and the most common patient-reported comor-
bid conditions were hypertension (n = 20, 51.3%) and
arthritis (n = 17, 43.6%). Norm-based scores of RAND-
36 were computed to a 0–100 score scale, where the
average health of the general population is around 50
with a SD of 10 [16]. In general, the participants
reported below-average physical health on the RAND-
36, but average mental health (Table 2).
The mean (SD) overall age was 61.6 (13.5) years for
the 12 cognitive interview participants. Most participants
were Caucasian (n = 8, 66.7%), female (n = 11, 91.7%),
and retired (n = 7, 58.3%), and the most common comor-
bid conditions reported by participants were arthritis
(n = 6, 50%) and hypertension (n = 5, 41.7%). Participants
reported experiencing bladder symptoms for an average
of 5.8 years.Clinician-reported clinical characteristics
As assessed by clinic staff, the 39 participants had been
patients at their respective clinics for a mean (SD) of 2.9
(2.4) years. Almost all participants’ (n = 35, 89.7%) pri-
mary urologic diagnosis was OAB; other primary diag-
noses included urge incontinence (n = 2), benign
prostatic hyperplasia (n = 1), and frequency (n = 1). Clini-
cians indicated most participants’ primary urinary com-
plaint as frequency (n = 27, 78.1%), followed by urgency
(n = 7, 17.9%). Based on the clinical chart, participants
were being prescribed the following medications: oxybu-
tynin (n = 12, 30.8%), solifenacin (n = 10, 25.6%), toltero-
dine (n = 6, 15.4%), darifenacin (n = 6, 15.4%), trospium
(n = 4, 10.2%), and estradiol cream (n = 1, 2.6%).
Of the 12 participants that completed the cognitive
interview, their primary clinician-reported urinary symp-
toms were frequency (n = 8, 66.7%), urgency (n = 3,
25.0%), and nocturia (n = 1, 8.3%). Secondary urinary
complaints included urgency (n = 7, 58.3%), incontinence
(n = 5, 41.7%), nocturia (n = 4, 33.3%), and frequency
(n = 2, 16.7%) (participants could indicate more than
one). The 12 participants were currently prescribed soli-
fenacin (n = 4, 33.3%), oxybutynin (n = 4, 33.3%), toltero-
dine (n = 3, 25.0%), and darifenacin (n = 1, 8.3%).
Table 2 Participant-reported demographic characteristics—cognitive interview participants
Test-retest study completer Cognitive interview completer
Characteristic N= 39 N=12*
Age (yrs)
Mean (SD) 59.1 (15.23) 61.6 (13.5)
Gender, n (%)
Male 7 (17.9%) 1 (8.3%)
Female 32 (82.1%) 11 (91.7%)
Race, n (%)
White 27 (69.2%) 8 (66.7%)
Black or African-American 3 (7.7%) 1 (8.3%)
Hispanic 3 (7.7%) 3 (25.0%)
Asian 6 (15.4%) 0 (0.0%)
Employment status, n (%)
Full-Time 8 (20.5%) 2 (16.7%)
Part-Time 6 (15.4%) 1 (8.3%)
Retired 13 (33.3%) 7 (58.3%)
Disabled 5 (12.8%) 1 (8.3%)
Others 5 (12.8%) 0 (0.0%)
Missing 2 (5.1%) 1 (8.3%)
Highest level of education, n (%)
Secondary/high school 10 (25.6%) 1 (8.3%)
Some college 17 (43.6%) 7 (58.3%)
Postgraduate degree 8 (20.5%) 2 (16.7%)
Other 4 (10.3%) 2 (16.7%)
Comorbid conditions n (%)
None 9 (23.1%) 3 (25.0%)
Arthritis 17 (43.6%) 6 (50.0%)
Cancer 1 (2.6%) 1 (8.3%)
Diabetes 7 (17.9%) 2 (16.7%)
Hypertension 20 (51.3%) 5 (41.7%)
Others 7 (17.9%) 0 (0.0%)
Length of time with bladder symptoms (yrs)
Mean (SD) 6.7 (6.78) 5.8 (4.6)
RAND SF-36 (mean, SD)
Physical component summary (PCS) 43.9(11.62) 44.5(12.77)
Mental component summary (MCS) 49.4 (9.45) 51.9 (9.54)
Physical function 42.9(13.39) 42.4(13.68)
Role physical 44.8(12.10) 45.0(12.23)
Bodily pain 47.4(11.32) 47.4(11.07)
General health 45.8(10.13) 50.0 (7.09)
Vitality 48.6 (8.57) 53.4 (8.06)
Social functioning 46.8(10.63) 45.4(12.21)
Role emotional 45.3(11.58) 52.4 (8.14)
Mental health 49.7 (8.13) 50.0 (7.09)
*12 of the 39 test-retest study completers were also participants in a cognitive interview.
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Urgency rating, micturition, and incontinence
The overall mean (SD) level of urgency was 2.0 (0.78) at
Week 1, 1.9 (0.91) at Week 2, and 2.0 (0.95) at Week 3.
The average ratings of urgency severity were stable over
the three weeks.
The mean (SD) number of micturition per 24-hours
was 10.0 (5.26) at Week 1, 10.3 (5.40) at Week 2, and
10.6 (5.70) at Week 3. The mean number of micturition
per 24-hours was stable over the three weeks.
The mean number of incontinence episodes per 24-
hour period was 2.2 (3.99) at Week 1, 2.0 (3.46) at Week
2, and 1.9 (4.16) at Week 3. Again, the mean number of
incontinence episodes per 24-hours was stable over the
three weeks.
Test-retest reliability
Thirty-four participants (87.2%) were classified as stable
based on the OTE-Patient and 35 participants (89.7%)
were classified as stable based on the OTE-Clinician.
Test-retest reliability of the PPIUS three-day mean score
in stable patients as classified based on the OTE-Patient
from Week 2 to Week 3 is shown in Table 3, with an
ICC of 0.95 and Spearman’s correlation of 0.89
(p < 0.0001). The difference in the mean values between
Weeks 2 and 3 was not statistically significant
(p = 0.3043). Similarly, test-retest reliability of the PPIUS
mean level of urgency in stable patients defined by the
OTE-Clinician from Week 2 to Week 3 was also high
(Table 3), with an ICC of 0.95, and Spearman’s correl-
ation of 0.89 (p < 0.0001). The difference in the mean
values between Weeks 2 and 3 was not statistically sig-
nificant (p = 0.2677).
Acclimation effect
No statistically significant differences were found in the
three-day mean PPIUS scores of stable patients between
Week 1 and Week 2 (difference= -0.05, t = -0.66,
p=0.5173), Week 2 and Week 3 (difference=0.01, t =0.08,
p=0.9348), or Week 1 and Week 3 (difference=0.05,
t = 1.04, p=0.3043). These results suggested that the PPIUS
did not demonstrate an acclimation effect in this study.Table 3 Test-retest reliability: PPIUS 3-day average scores in s
PPIUS score Mean (SD) Week 2 Mean (SD) Week 3 D
3-day Average Score 2.0 (0.91) 2.1 (0.94)
3-day Average Score 2.0 (0.90) 2.1 (0.93)
1 Evaluated in stable patients defined as scores of -1, 0, or 1 by the OTE-Patient.
2 Patients who have average scores at both weeks.
3 Week 3 average score – Week 2 average.
4 Spearman rank order correlations; * p < 0.05; **p < 0.001; ***p < 0.0001.
5 Intra-class correlation coefficient.Qualitative results from the cognitive interview (n = 12)
During the cognitive interviews, participants described
their thought process for completing the three-day diary
including the PPIUS. Participants were asked for their
interpretation of the diary instructions and to describe
their experience completing the three-day diary. Partici-
pants were asked about their understanding of the defi-
nitions of the urgency ratings and whether they were
consistent with their own experiences and interpretation
of the rating terms. Finally, the participants were asked
about the formatting and feasibility of completing the
diary on a daily basis for an extended period of time.
Diary instructions
Participants were asked to summarize the diary instruc-
tions for diary completion in their own words. Nine par-
ticipants (75.0%) were able to accurately summarize the
instructions. Half of participants (n = 6, 50.0%) felt that
the instructions were clear and did not need any
changes. Suggestions for modifying the instructions
included clarifying the 12-hour clock as opposed to mili-
tary time (n = 2, 16.7%) and providing more instructions
about when to record episodes as “daytime” or “night-
time” (n = 3, 25.0%).
Overall experience
Participants were also asked to speak about their overall
experience with the three-day diary. Ten participants
(83.0%) said they had no difficulty completing the diary.
Six participants (50.0%) expressed a positive opinion of
the diary. Others (n = 2, 16.7%) reported that they had
trouble remembering to complete the diary, found the
diary inconvenient (n = 1, 8.3%), or were bothered by
having to record urinations at night (n = 1, 8.3%).
Definition of urgency ratings
Participants were asked if the definitions of the urgency
ratings were clear. Nine participants (75.0%) reported
that the definition provided for “No urgency” was con-
sistent with their interpretation of the phrase. Seven par-
ticipants (58.3%) indicated that the definition of “Mild
urgency” was consistent with the way they think of thetable patients1 week 2 to week 3 (n= 34)2
ifference3 (SD) T-value P-value Spearman’s r4 ICC5
OTE-Patient
0.05 (0.294) 1.04 0.3043 0.89*** 0.95
OTE-Clinician
0.06 (0.290) 1.13 0.2677 0.89*** 0.95
Notte et al. BMC Urology 2012, 12:26 Page 7 of 8
http://www.biomedcentral.com/1471-2490/12/26phrase. Eight participants (66.7%) and nine participants
(75.0%), respectively, found the definitions of “Moderate
urgency” and “Severe urgency” to be consistent with
their interpretation of the phrases. When asked about
the definition provided for “Urge incontinence,” nine
participants (75.0%) felt that the definition was consist-
ent with their interpretation of the phrase. Notable sug-
gestions came from two participants for simplifying the
definition by changing the word “postpone” to “delay;”
and revising the definition of “Moderate urgency” from
“I could postpone voiding . . ..without fear of wetting my-
self” to “I could postpone voiding for a longer period.”Formatting and feasibility
Because the participants rated their PPIUS rating on a
micturition diary, they were also asked about the diary
itself. Seven participants (58.3%) responded positively to
the diary formatting and described it as “wonderful,”
“organized,” “good,” “self explanatory,” “great,” and “well
done.” Participants were then asked to describe a typical
day when they completed the diary. Seven participants
(58.3%) said they kept the diary by their bed at night. Six
participants (50.0%) said they completed their diary
entry after each episode, while three participants
recorded the episode on a separate sheet of paper after
each episode and transferred the information to the
diary at a later time.Discussion
In order to assess content validity and test-retest reliabil-
ity of the PPIUS, this study recruited OAB patients to
complete a three-day micturition diary including the
PPIUS for three consecutive weeks followed by cognitive
interviews with participants at selected sites.
During the cognitive interview, participants were
debriefed on the entire diary including the instruc-
tions, the urgency rating scale of the PPIUS, and
their overall experience with the diary and complet-
ing it for three weeks. The interviews ascertained
that participants interpreted the PPIUS as intended,
with most participants reporting that they under-
stood the urgency rating definitions, did not have
difficulty rating their urgency grade for each mictur-
ition, and found the definitions to be consistent with
their interpretation of the rating terms. Participants
also reported that they liked and referred to the full
urgency rating definitions that were included in the
diary instruction packet.
Test-retest reliability of the PPIUS was assessed in 39
patients with OAB receiving pharmacological treatment
for their symptoms. Reproducibility was excellent, as evi-
denced by high ICCs and Spearman’s correlations. In
addition, paired t-tests found no difference of PPIUSthree-day mean scores between any two weeks supporting
that the PPIUS did not demonstrate an acclimation effect.
Although the PPIUS was based on the definition rec-
ommend by ICS Standardization of Terminology of
Lower Urinary Tract Function Report [1] and the Com-
mittee for Proprietary Medical Products Standardization
Sub-Committee [3], and has been used in other clinical
studies [4-6], this is the first attempt in investigating the
content validity of the PPIUS from the perspective of
OAB patients. While cognitive interview participants
were recruited from only two sites, the participants con-
sisted of a good representation of age range, education
level, comorbid conditions, and races. In addition, parti-
cipants also were interviewed shortly after completing
the diary for three consecutive weeks, to ensure partici-
pants could accurately recall their experience with the
diary. The study results are representative and reliable.
Several limitations should be kept in mind when inter-
preting these results. First, previous studies have indi-
cated that OAB was almost equally prevalent among
men and women [17-20]. However, a relatively small
percentage (18%) of men participated in the study, while
target enrollment for men in OAB clinical trials is typic-
ally about 30%. The results could be more confidently
generalized to the male patient population if more male
patients were interviewed. Another limitation was that
the urgency and incontinence continuum was not fully
explored, which remained a challenge in assessing urin-
ary urgency. One participant described experiencing in-
continence at all level of urgency. Further studies are
needed as Starkman et al [21]. pointed out “While some
argue that urgency is episodic and maximal, we believe
it can be subjectively graded. For example, some epi-
sodes of urgency can be suppressed, some persistently
require immediate action, and some are so overwhelm-
ing that urge incontinence results. Although evidence
for such a continuum is lacking, it remains conceptually
intuitive.” PPIUS has been included in two completed,
one withdrawn, and one ongoing clinical trial as shown
in the ClinicalTrial.gov website.
Conclusions
Participants in general demonstrated good understanding
of the PPIUS instructions and found the ratings of ur-
gency severity to be consistent with their interpretation of
the ratings. Results of the cognitive interviews demon-
strated evidence of content validity of the PPIUS, as parti-
cipants in general agreed with the definition of the
urgency ratings, finding the definitions consistent with
their experiences. The PPIUS demonstrated excellent test-
retest reliability as evidenced by high ICC in stable
patients classified by both the OTE-Patient (ICC= 0.95)
and the OTE-Clinician (ICC=0.95). Acclimation effect
was not observed among stable patients completing the
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port the use of the PPIUS as a reliable measure of urgency
in both clinical trial and real life settings. The validity of
PPIUS may be further established with future studies in-
vestigating the relationship between discretely graded ur-
gency and incontinence continuum.
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